Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Bioxytran===ProLectin-M
Entity

Bioxytran===ProLectin-M

Tracked across 1 events · 19 articles · First seen Jan 29, 2026 · Last active Feb 17, 2026

Sentiment
85
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 85
Tech
Bioxytran ProLectin-M Phase 2 Success
Bioxytran===ProLectin-M, Bioxytran's lead drug candidate, demonstrated rapid and sustained viral clearance in its Phase 2 trial. These strong results validate its novel mechanism of action and support its potential as a broad-spectrum antiviral therapeutic, increasing its value and future market prospects.
Jan 29, 2026 · 19 articles
NEWSDESK
Track Bioxytran===ProLectin-M live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.